RITONAVIR

Post-LOESM

ritonavir

Hetero

ANDAORALTABLET

Approved

Sep 2018

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

RITONAVIR (ritonavir) by Hetero is hiv protease inhibitors [moa]. Approved for combination with other antiretroviral agents for the treatment of hiv-1 infection ( ). First approved in 2018.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

HIV Protease Inhibitors

Pharmacologic Class:

Cytochrome P450 3A Inhibitor

Indications (1)

combination with other antiretroviral agents for the treatment of HIV-1 infection ( )

Clinical Trials (20)

NCT00001133Phase 1Completed

Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

50 enrolled

HIV Infections

NCT00063804Phase 1Completed

Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men

44 enrolled

HIV Infections

NCT00001075N/ACompleted

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

55 enrolled

HIV Infections

NCT00004580Phase 1Completed

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

HIV Infections

NCT00028366N/ACompleted

Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People

56 enrolled

HIV Infections

Worked on RITONAVIR at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.